Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCD | Q05655 | 11/20 | 0.73 |
| ▸ | PRKCA | P17252 | 8/20 | 0.73 |
| ▸ | PRKCG | P05129 | 7/20 | 0.73 |
| ▸ | PRKCB | P05771 | 6/20 | 0.68 |
| ▸ | PRKCE | Q02156 | 6/20 | 0.68 |
| ▸ | PRKCH | P24723 | 5/20 | 0.68 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.68 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.68 |
| ▸ | PRKCI | P41743 | 4/20 | 0.68 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.68 |
| ▸ | PRKD1 | Q15139 | 4/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31662590 | 1.00 | PRKCD (0.73) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| SCHEMBL31662631 | 1.00 | PRKCD (0.73) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| SCHEMBL31662763 | 1.00 | PRKCD (0.73) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| SCHEMBL12225926 | 0.88 | PRKCD (0.73) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| SCHEMBL31662666 | 0.86 | PRKCD (0.70) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| SCHEMBL31662575 | 0.85 | PRKCD (0.69) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| SCHEMBL31662772 | 0.85 | PRKCD (0.69) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| SCHEMBL25138772 | 0.84 | PRKCD (1.00) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| SCHEMBL31662410 | 0.84 | PRKCD (1.00) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| SCHEMBL30010317 | 0.84 | PRKCD (1.00) | PRKCDPRKCAPRKCGPRKCBPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151449-A1 | BIFUNCTIONAL P53-BINDING COMPOUNDS AND USES THEREOF | PHOTYS THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| US-20110257145-A1 | METHOD OF TREATING NEUROLOGICAL DISEASES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257145-A1 | METHOD OF TREATING NEUROLOGICAL DISEASES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257145-A1 | METHOD OF TREATING NEUROLOGICAL DISEASES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257145-A1 | METHOD OF TREATING NEUROLOGICAL DISEASES | PRKCA, PYGB, PNCK | PRKCD 87/4885PRKCA 1/4885PRKCG 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.